Work

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Year: 2009

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet

DOI: 10.1016/s0140-6736(09)60506-7

Authors: Josef S Smolen, Jonathan Kay, Mittie K Doyle, Robert Landewé, Eric L Matteson, Jürgen Wollenhaupt, Norman Gaylis, Frederick T Murphy, Jeffrey S Neal, Yiying Zhou, Sudha Visvanathan, Elizabeth C Hsia, Mahboob U Rahman

Institutions: Klinik Hietzing, Medical University of Vienna, Harvard University, Massachusetts General Hospital, University of Pennsylvania, Maastricht University Medical Centre, Mayo Clinic, Schön Klinik Hamburg Eilbek, Arthritis and Rheumatic Disease Specialties, Altoona Center for Clinical Research

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W2140965629

FWCI: 39.12

Cites: 39

Cited by: 526

Related to: 10